Stephen Jacob Goldfless

USPTO Granted Patents = 13 (Patent Applications = 8)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 4.9

ph-index = 2

Forward Citations = 10(Granted Patents)

Location History:

Cambridge, MA (US) (2015 - 2020)
Seattle, WA (US) (2019 - 2024)

Company Filing History:

Juno Therapeutics Gmbh

patents

1 out of 50

Editas Medicine, Inc.

patents

4. 1 out of 8,369

Massachusetts Institute of Technology

patents

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12268741 - Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1) (2025-04-08),

2. 12049667 - High-throughput polynucleotide library sequencing and transcriptome analysis (2024-07-30),

3. 11952408 - HPV-specific binding molecules (2024-04-09),

4. 11572403 - Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope (2023-02-07),

5. 11471489 - T cell receptors and engineered cells expressing same (2022-10-18),

6. 11156611 - Single cell characterization using affinity-oligonucleotide conjugates and vessel barcoded polynucleotides (2021-10-26),

7. 11142565 - Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope (2021-10-12),

8. 11061030 - Affinity-oligonucleotide conjugates and uses thereof (2021-07-13),

9. 10982258 - Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens (2021-04-20),

10. 10928392 - High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences (2021-02-23),

11. 10590483 - High-throughput nucleotide library sequencing (2020-03-17),

12. 10393743 - Methods of selecting T cell receptors using affinity oligonucleotide conjugates (2019-08-27),

13. 9125931 - Post-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers (2015-09-08),

Title: The Innovative Contributions of Stephen Jacob Goldfless

Introduction

Stephen Jacob Goldfless is a prominent inventor based in Seattle, WA, known for his significant contributions to the field of biotechnology. With a total of 13 patents to his name, Goldfless has made remarkable advancements, particularly in the development of therapeutic antibodies and gene sequencing technologies. His work has had a profound impact on the medical and scientific communities.

Latest Patents

Goldfless's latest patents include groundbreaking innovations such as antibodies and chimeric antigen receptors specific for receptor tyrosine kinase-like orphan receptor 1 (ROR1). This patent provides receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, particularly human antibodies specific for ROR1, including antibody fragments. The disclosure also relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode these antibodies, antigen-binding fragments, or receptors specific for ROR1. Additionally, he has developed methods for high-throughput polynucleotide library sequencing and transcriptome analysis, which allow for target gene sequencing and single-cell barcoding in conjunction with gene expression analysis in single cells.

Career Highlights

Throughout his career, Goldfless has worked with notable companies in the biotechnology sector, including Abvitro LLC and Juno Therapeutics GmbH. His expertise in the field has led to significant advancements in therapeutic applications and research methodologies.

Collaborations

Goldfless has collaborated with esteemed colleagues such as Francois Vigneault and Adrian Wrangham Briggs, contributing to the advancement of innovative solutions in biotechnology.

Conclusion

Stephen Jacob Goldfless is a distinguished inventor whose work in biotechnology continues to influence the development of novel therapeutic strategies and research techniques. His contributions are invaluable to the ongoing progress in the field.

This text is generated by artificial intelligence and may not be accurate.